NasdaqCM - Delayed Quote USD

Medicus Pharma Ltd. (MDCX)

2.5500
-1.0850
(-29.85%)
At close: May 30 at 4:00:02 PM EDT
2.5300
-0.02
(-0.78%)
After hours: May 30 at 7:32:56 PM EDT
Loading Chart for MDCX
  • Previous Close 3.6350
  • Open 3.0100
  • Bid 2.4100 x 100
  • Ask 2.7000 x 100
  • Day's Range 2.3400 - 3.0400
  • 52 Week Range 1.8000 - 8.9400
  • Volume 1,944,091
  • Avg. Volume 164,773
  • Market Cap (intraday) 34.412M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.15

Medicus Pharma Ltd., a biotech/life sciences company, focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers. The company was founded in 2015 and is headquartered in Toronto, Canada.

medicuspharma.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: MDCX

View More

Performance Overview: MDCX

Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDCX
4.94%
S&P 500 (^GSPC)
0.51%

1-Year Return

MDCX
17.74%
S&P 500 (^GSPC)
12.92%

3-Year Return

MDCX
17.74%
S&P 500 (^GSPC)
42.17%

5-Year Return

MDCX
17.74%
S&P 500 (^GSPC)
94.19%

Compare To: MDCX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MDCX

View More

Valuation Measures

Annual
As of 5/30/2025
  • Market Cap

    34.48M

  • Enterprise Value

    30.79M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    16.06

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -1.3700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: MDCX

View More

Company Insights: MDCX

Research Reports: MDCX

View More

People Also Watch